- E( @' x+ W. a: M# C7 P+ K5 F" V
麻烦大叔告诉我第三个的理由是什么?
4 H4 T8 e: u1 h8 O6 i
临床上有依维莫司联合EGFR TKI作为易/特耐药之后的方案的研究:0 A; a# @* i) a. t
Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer. 5 O0 _) R H0 @9 Q5 u8 d0 G: @http://www.ncbi.nlm.nih.gov/pubmed/22968184* I; N& X, |7 I1 s8 _2 v